{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T23:10:18Z","timestamp":1795216218895,"version":"4.10.3"},"reference-count":47,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C2195\/A31310"],"award-info":[{"award-number":["C2195\/A31310"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C5255\/A18085"],"award-info":[{"award-number":["C5255\/A18085"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2022,6,14]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Prior studies identified clinical factors associated with increased risk of pancreatic ductal adenocarcinoma (PDAC). However, little is known regarding their time-varying nature, which could inform earlier diagnosis. This study assessed temporality of body mass index (BMI), blood-based markers, comorbidities and medication use with PDAC risk .<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We performed a population-based nested case\u2013control study of 28 137 PDAC cases and 261 219 matched-controls in England. We described the associations of biomarkers with risk of PDAC using fractional polynomials and 5-year time trends using joinpoint regression. Associations with comorbidities and medication use were evaluated using conditional logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Risk of PDAC increased with raised HbA1c, liver markers, white blood cell and platelets, while following a U-shaped relationship for BMI and haemoglobin. Five-year trends showed biphasic BMI decrease and HbA1c increase prior to PDAC; early-gradual changes 2\u20133 years prior, followed by late-rapid changes 1\u20132 years prior. Liver markers and blood counts (white blood cell, platelets) showed monophasic rapid-increase approximately 1 year prior. Recent diagnosis of pancreatic cyst, pancreatitis, type 2 diabetes and initiation of certain glucose-lowering and acid-regulating therapies were associated with highest risk of PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Risk of PDAC increased with raised HbA1c, liver markers, white blood cell and platelets, while followed a U-shaped relationship for BMI and haemoglobin. BMI and HbA1c derange biphasically approximately 3 years prior while liver markers and blood counts (white blood cell, platelets) derange monophasically approximately 1 year prior to PDAC. Profiling these in combination with their temporality could inform earlier PDAC diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2021-326522","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T13:27:18Z","timestamp":1656336438000},"page":"512-521","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case\u2013control study"],"prefix":"10.1136","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3359-1874","authenticated-orcid":false,"given":"Pui San","family":"Tan","sequence":"first","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7073-3611","authenticated-orcid":false,"given":"Cesar","family":"Garriga","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Clift","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"},{"name":"Department of Oncology, Cancer Research UK Oxford Centre, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Liao","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Patone","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Coupland","sequence":"additional","affiliation":[{"name":"Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Bashford-Rogers","sequence":"additional","affiliation":[{"name":"Wellcome Centre for Human Genomics, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivan","family":"Sivakumar","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Oxford, Oxford, UK"},{"name":"Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK"},{"name":"Department of Oncology, Oxford University Hospitals NHS Foundation Trusts, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hippisley-Cox","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"2025121219450484000_72.3.512.1","unstructured":"CRUK . Pancreatic cancer statistics. 2015-05-14, 2015. Available: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/pancreatic-cancer"},{"key":"2025121219450484000_72.3.512.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.45"},{"key":"2025121219450484000_72.3.512.3","unstructured":"CRUK . Survival | pancreatic cancer | cancer research UK, 2020. Available: https:\/\/www.cancerresearchuk.org\/about-cancer\/pancreatic-cancer\/survival"},{"key":"2025121219450484000_72.3.512.4","unstructured":"Medicine JH . Pancreatic cancer prognosis, 2020. Available: https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/pancreatic-cancer\/pancreatic-cancer-prognosis"},{"key":"2025121219450484000_72.3.512.5","unstructured":"Network PCA . Types of pancreatic cancer \u2013 pancreatic cancer action network, 2020."},{"key":"2025121219450484000_72.3.512.6","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp12X616355"},{"key":"2025121219450484000_72.3.512.7","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2021.0153"},{"key":"2025121219450484000_72.3.512.8","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.253"},{"key":"2025121219450484000_72.3.512.9","doi-asserted-by":"publisher","DOI":"10.2337\/db16-1477"},{"key":"2025121219450484000_72.3.512.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-007825"},{"key":"2025121219450484000_72.3.512.11","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.cgh.2019.11.043","article-title":"New-Onset Diabetes, Longitudinal Trends in Metabolic Markers, and Risk of Pancreatic Cancer in a Heterogeneous Population","volume":"18","author":"Huang","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121219450484000_72.3.512.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-010-9686-3"},{"key":"2025121219450484000_72.3.512.13","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/cncr.10493","article-title":"A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus","volume":"94","author":"Ogawa","year":"2002","journal-title":"Cancer"},{"key":"2025121219450484000_72.3.512.14","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.2948","article-title":"Diabetes, weight change, and pancreatic cancer risk","volume":"6","author":"Yuan","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025121219450484000_72.3.512.15","unstructured":"NICE . Overview | suspected cancer: recognition and referral | guidance | NICE, 2015."},{"key":"2025121219450484000_72.3.512.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001989"},{"key":"2025121219450484000_72.3.512.17","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-07-0507"},{"key":"2025121219450484000_72.3.512.18","unstructured":"UK CR . Blood tests for pancreatic cancer, 2021. Available: https:\/\/www.cancerresearchuk.org\/about-cancer\/pancreatic-cancer\/getting-diagnosed\/tests\/blood-tests"},{"key":"2025121219450484000_72.3.512.19","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-18-0421"},{"key":"2025121219450484000_72.3.512.20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ijc.31866","article-title":"Pancreatic cancer and autoimmune diseases: an association sustained by computational and epidemiological case-control approaches","volume":"144","author":"Gomez-Rubio","year":"2019","journal-title":"Int J Cancer"},{"key":"2025121219450484000_72.3.512.21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25148"},{"key":"2025121219450484000_72.3.512.22","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-12-0195"},{"key":"2025121219450484000_72.3.512.23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13430-z","article-title":"Exclusive and combined use of statins and aspirin and the risk of pancreatic cancer: a case-control study","volume":"7","author":"Archibugi","year":"2017","journal-title":"Sci Rep"},{"key":"2025121219450484000_72.3.512.24","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009101043"},{"key":"2025121219450484000_72.3.512.25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canep.2016.12.006","article-title":"Proton pump inhibitors on pancreatic cancer risk and survival","volume":"46","author":"Kearns","year":"2017","journal-title":"Cancer Epidemiol"},{"key":"2025121219450484000_72.3.512.26","first-page":"100","article-title":"Proton pump inhibitors and histamine-2 receptor antagonists on the risk of pancreatic cancer: a systematic review and meta-analysis","volume":"113","author":"Laoveeravat","year":"2020","journal-title":"QJM"},{"key":"2025121219450484000_72.3.512.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-27965-2","article-title":"The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep"},{"key":"2025121219450484000_72.3.512.28","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018033","article-title":"Aspirin use and pancreatic cancer risk: a systematic review of observational studies","volume":"98","author":"Sun","year":"2019","journal-title":"Medicine"},{"key":"2025121219450484000_72.3.512.29","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.383"},{"key":"2025121219450484000_72.3.512.30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/jcm7080197","article-title":"Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Women\u2019s Health Initiative Study","volume":"7","author":"Wang","year":"2018","journal-title":"J Clin Med"},{"key":"2025121219450484000_72.3.512.31","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.257"},{"key":"2025121219450484000_72.3.512.32","doi-asserted-by":"crossref","first-page":"34727","DOI":"10.18632\/oncotarget.16151","article-title":"Digitalis use and risk of gastrointestinal cancers: a nationwide population-based cohort study","volume":"8","author":"Xie","year":"2017","journal-title":"Oncotarget"},{"key":"2025121219450484000_72.3.512.33","unstructured":"Townsend P , Davidson N . Inequalities in health: the black report, 1982."},{"key":"2025121219450484000_72.3.512.34","unstructured":"Joinpoint trend analysis software. Available: https:\/\/surveillance.cancer.gov\/joinpoint\/2021"},{"key":"2025121219450484000_72.3.512.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e02515","article-title":"The utility of joinpoint regression for estimating population parameters given changes in population structure","volume":"5","author":"Gillis","year":"2019","journal-title":"Heliyon"},{"key":"2025121219450484000_72.3.512.36","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z"},{"key":"2025121219450484000_72.3.512.37","doi-asserted-by":"crossref","unstructured":"Rubin D . Multiple imputation for non-response in surveys. John Wiley, 1987.","DOI":"10.1002\/9780470316696"},{"key":"2025121219450484000_72.3.512.38","unstructured":"STATA . Graph twoway fpfit. STATA."},{"key":"2025121219450484000_72.3.512.39","unstructured":"Mathur MB , Smith LH , Ding P . Package \u2018EValue\u2019, 2021."},{"key":"2025121219450484000_72.3.512.40","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"2025121219450484000_72.3.512.41","unstructured":"StataCorp . Stata statistical software: release 17. College Station, TX: StataCorp LLC, 2021."},{"key":"2025121219450484000_72.3.512.42","unstructured":"Diabetes as a risk pathway towards early diagnosis and prognostication of pancreatic cancer. Available: https:\/\/www.qresearch.org\/research\/approved-research-programs-and-projects\/diabetes-as-a-risk-pathway-towards-early-diagnosis-and-prognostication-of-pancreatic-cancer\/2021"},{"key":"2025121219450484000_72.3.512.43","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.2147\/CMAR.S211151","article-title":"Brca mutations in pancreas cancer: spectrum, current management, challenges and future prospects","volume":"12","author":"Wong","year":"2020","journal-title":"Cancer Manag Res"},{"key":"2025121219450484000_72.3.512.44","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S206949"},{"key":"2025121219450484000_72.3.512.45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/4986365","article-title":"Brca mutations in prostate cancer: prognostic and predictive implications","volume":"2020","author":"Messina","year":"2020","journal-title":"J Oncol"},{"key":"2025121219450484000_72.3.512.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2009.02.001"},{"key":"2025121219450484000_72.3.512.47","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.cgh.2021.05.034","article-title":"Cancer risk in 47,241 individuals with celiac disease: a nationwide cohort study","volume":"20","author":"Lebwohl","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2021-326522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:45:20Z","timestamp":1765597520000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2021-326522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2,7]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/gutjnl-2021-326522"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2021-326522","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]}}}